Probiotic intervention decreases serum gastrin-17 in Helicobacter pylori infection.
BACKGROUND
Previously we showed that a probiotic combination with L. rhamnosus GG was beneficial as an adjuvant therapy during H. pylori eradication.


OBJECTIVE
To evaluate whether probiotic combination with LGG adheres to the upper gastrointestinal mucosa and modifies H. pylori colonisation and H. pylori induced inflammation.


METHODS
Thirteen patients referred for gastroduodenoscopy received a drink consisting of equal doses (2.5x10(9)CFU) of LGG, L. rhamnosus LC705, Propionibacterium freudenreichii JS and Bifidobacterium lactis Bb12 daily. Recovery of probiotics in biopsies (antrum, corpus, duodenum) and faecal samples was evaluated by strain-specific quantitative polymerase chain reaction. H. pylori colonization and gastric inflammation was investigated by urease activity ((13)C-urea breath test), histology and serum pepsinogen I, II and gastrin-17 measurements.


RESULTS
Twelve patients were fully investigated; of these three of the patients had LGG adhering to the biopsies at end of the intervention. Other probiotic strains were not detected, even though the recovery of all individual probiotic strains from the faeces was significantly increased (p<0.01). After the treatment, the level of (13)C-urea breath test (p=0.063) and gastrin-17 (p=0.046) decreased.


CONCLUSIONS
The decreases in (13)C-urea breath test and gastrin-17 indicate that the probiotic combination exerts a beneficial effect on gastric mucosa in H. pylori infected patients. LGG showed marginal ability to adhere to the upper gastrointestinal tract mucosa.
Myllyluoma
E
E
Institute of Biomedicine, Pharmacology, University of Helsinki, Finland.
Kajander
K
K
Mikkola
H
H
Kyrönpalo
S
S
Rasmussen
M
M
Kankuri
E
E
Sipponen
P
P
Vapaatalo
H
H
Korpela
R
R
D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D001706:Biopsy; D004269:DNA, Bacterial / Q000032:analysis / Q000235:genetics; D005243:Feces / Q000382:microbiology; D005260:Female; D005753:Gastric Mucosa / Q000473:pathology; D005755:Gastrins / Q000097:blood*; D016481:Helicobacter Infections / Q000097:blood* / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000235:genetics / Q000302:isolation & purification; D006801:Humans; D008297:Male; D008875:Middle Aged; D010435:Pepsinogens / Q000097:blood; D019936:Probiotics / Q000627:therapeutic use*
D015415:Biomarkers; D004269:DNA, Bacterial; D005755:Gastrins; D010435:Pepsinogens; C013550:gastrin 17